Literature DB >> 29226578

Ischemia-reperfusion injury and ischemic post-conditioning in acute myocardial infarction: Lost in translation.

Gennaro Giustino1, George D Dangas1.   

Abstract

Ischemic post-conditioning (IPoC) has been proposed as a strategy to mitigate the risk of ischemia-reperfusion injury during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). In this comprehensive and updated meta-analysis of randomized controlled trials, IPoC during primary PCI for STEMI had no significant effect on all-cause mortality, re-infarction, or new-onset heart failure compared with no post-conditioning. Further strategies need to be prospectively evaluated to improve outcomes in patients with STEMI undergoing primary PCI.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 29226578     DOI: 10.1002/ccd.27436

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Meteorin-Like (METRNL) Attenuates Myocardial Ischemia/Reperfusion Injury-Induced Cardiomyocytes Apoptosis by Alleviating Endoplasmic Reticulum Stress via Activation of AMPK-PAK2 Signaling in H9C2 Cells.

Authors:  Ling Xu; Yinlian Cai; Yaoguo Wang; Chaoxiang Xu
Journal:  Med Sci Monit       Date:  2020-06-28

Review 2.  Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection.

Authors:  Afonso Caricati-Neto; Paolo Ruggero Errante; Francisco Sandro Menezes-Rodrigues
Journal:  Int J Mol Sci       Date:  2019-08-16       Impact factor: 5.923

3.  MicroRNA-668-3p Protects Against Oxygen-Glucose Deprivation in a Rat H9c2 Cardiomyocyte Model of Ischemia-Reperfusion Injury by Targeting the Stromal Cell-Derived Factor-1 (SDF-1)/CXCR4 Signaling Pathway.

Authors:  Zhan Gao; Qiang Gao; Xiaodong Lv
Journal:  Med Sci Monit       Date:  2020-01-30

4.  Cardioprotective effects of co-administration of thymoquinone and ischemic postconditioning in diabetic rats.

Authors:  Junchuan Ran; Huanglin Xu; Wenyuan Li
Journal:  Iran J Basic Med Sci       Date:  2021-07       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.